A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Clinical trial NCT06703892 · RECRUITING

Trial details

NCT number: NCT06703892
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Relapsed Diffuse Large B Cell Lymphoma Refractory Follicular Lymphoma ( FL)Primary Mediastinal Large B-Cell Lymphoma-Refractory Primary Mediastinal Large B-Cell Lymphoma-Recurrent High-grade B-cell Lymphoma (HGBCL)

Start date: 2025-06-09
Primary completion: 2027-03-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.